Sustained ligand-activated preconditioning via δ-opioid receptors.
We have previously described novel cardioprotection in response to sustained morphine exposure, efficacious in young to aged myocardium and mechanistically distinct from conventional opioid or preconditioning (PC) responses. We further investigate opioid-dependent sustained ligand-activated preconditioning (SLP), assessing duration of protection, opioid receptor involvement, additivity with conventional responses, and signaling underlying preischemic induction of the phenotype. Male C57BL/6 mice were treated with morphine (75-mg subcutaneous pellet) for 5 days followed by morphine-free periods (0, 3, 5, or 7 days) before ex vivo assessment of myocardial tolerance to 25-min ischemia/45-min reperfusion. SLP substantially reduced infarction (by ∼50%) and postischemic contractile dysfunction (eliminating contracture, doubling force development). Cardioprotection persisted for 5 to 7 days after treatment. SLP was induced specifically by δ-receptor and not κ- or μ-opioid receptor agonism, was eliminated by δ-receptor and nonselective antagonism, and was additive with adenosinergic but not acute morphine- or PC-triggered protection. Cotreatment during preischemic morphine exposure with the phosphoinositide-3 kinase (PI3K) inhibitor wortmannin, but not the protein kinase A (PKA) inhibitor myristoylated PKI-(14-22)-amide, prevented induction of SLP. This was consistent with shifts in total and phospho-Akt during the induction period. In summary, data reveal that SLP triggers sustained protection from ischemia for up to 7 days after stimulus, is δ-opioid receptor mediated, is induced in a PI3K-dependent/PKA-independent manner, and augments adenosinergic protection. Mechanisms underlying SLP may be useful targets for manipulation of ischemic tolerance in young or aged myocardium.
Peart
Jason N
JN
Heart Foundation Research Centre, Griffith University, Southport, Australia. j.peart@griffith.edu.au
Hoe
Louise E See
LE
Gross
Garrett J
GJ
Headrick
John P
JP
D000818:Animals; D003692:Delayed-Action Preparations / Q000008:administration & dosage; D019157:Ischemic Preconditioning, Myocardial / Q000379:methods; D008024:Ligands; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009020:Morphine / Q000008:administration & dosage*; D009200:Myocardial Contraction / Q000502:physiology; D017465:Receptors, Opioid, delta / Q000819:agonists* / Q000378:metabolism*; D013997:Time Factors
D003692:Delayed-Action Preparations; D008024:Ligands; D017465:Receptors, Opioid, delta; D009020:Morphine